Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4313 results
X-Chem, Bayer expand drug discovery collaboration
By PBR Staff Writer
X-Chem and Bayer have expanded a global drug discovery collaboration launched in 2012 across several therapeutic areas and target classes.
Drug Research > Drug Discovery & Development > News
Evotec, ANTRUK collaborate to discover antibiotic resistance breakers
By PBR Staff Writer
Evotec and Antibiotic Research UK (ANTRUK) have partnered to discover antibiotic resistance breakers (ARBs).
Drug Research > Drug Discovery & Development > News
Sprint Bioscience collaborates with US drug development firm on tumor metabolism program
Sprint Bioscience and a US drug development company have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism.
Drug Research > Drug Discovery & Development > News
Vertex and Moderna partner to develop mRNA Therapeutics for cystic fibrosis
By PBR Staff Writer
Vertex Pharmaceuticals and Moderna Therapeutics have partnered messenger Ribonucleic Acid (mRNA) Therapeutics for the treatment of cystic fibrosis (CF).
Drug Research > Drug Discovery & Development > News
Carmot Therapeutics establishes drug discovery collaboration with Genentech
Carmot Therapeutics has entered into a drug discovery collaboration and license agreement with Genentech, a member of the Roche Group.
Drug Research > Drug Discovery & Development > News
BioCryst receives additional NIAID funding to advance development of BCX4430
BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided additional funding for efficacy studies of BCX4430 in non-human primates to further assess effective dose regimens.
Drug Research > Drug Discovery & Development > News
Aviragen Therapeutics, GSURF sign deal to develop novel antiviral therapies
Aviragen Therapeutics has entered into an exclusive, worldwide license and sponsored research agreement with Georgia State University Research Foundation (GSURF) to jointly develop and commercialize respiratory syncytial virus (RSV) replication inhibitors discovered by Professor Richard Plemper and his team in the Institute for Biomedical Sciences (IBMS) at Georgia State University.
Drug Research > Drug Discovery & Development > News
Takeda partners with Altos Therapeutics to develop ATC-1906 for gastroparesis treatment
By PBR Staff Writer
Takeda Pharmaceutical is supporting Altos Therapeutics to help it move forward with the development of its ATC-1906 compound to treat gastroparesis (GP).
Drug Research > Drug Discovery & Development > News
Citius Pharmaceuticals discontinues Suprenza to focus on core assets
Citius Pharmaceuticals is discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss.
Drug Research > Drug Discovery & Development > News
Heptares, leadXpro partner on powerful new approaches to GPCR structure determination for drug discovery
Heptares Therapeutics and leadXpro, a new spin off from the Paul Scherrer Institute (PSI), announce a collaboration to employ powerful new approaches for the determination of high-resolution X-ray structures of G protein-coupled receptors (GPCRs) to discover new drug lead compounds.
Drug Research > Drug Discovery & Development > News
Merck, Moderna partner to develop mRNA-based personalized cancer vaccines
By PBR Staff Writer
Merck and Moderna Therapeutics have partnered to develop and commercialize novel messenger RNA (mRNA)-based personalized personalized cancer vaccines.
Drug Research > Drug Discovery & Development > News
Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
Onxeo announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA repair to induce cancer cell death.
Drug Research > Drug Discovery & Development > News
Hengrui Therapeutics unveils $100m investment from HR Bio Holdings for global clinical development
Hengrui Therapeutics (HTI) has signed an agreement with HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd. (JHM) and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI.
Drug Research > Drug Discovery & Development > News
Gene-editing firm CRISPR Therapeutics raises additional $38M in Series B Financing
By PBR Staff Writer
Gene-editing firm CRISPR Therapeutics has raised an additional $38m as part of series B financing, bringing the total investment in the round to about $140m.
Drug Research > Drug Discovery & Development > News
Pfizer acquires Anacor Pharmaceuticals for $5.2bn
By PBR Staff Writer
Pfizer has acquired Anacor Pharmaceuticals, which is engaged in the discovery, development and commercialization of novel small-molecule therapeutics, for $5.2bn.
Drug Research > Drug Discovery & Development > News
91-105 of 4313 results